Applied Therapeutics Inc (NASDAQ: APLT) has experienced a rise in its stock price by 1.94 compared to its previous closing price of 6.27. However, the company has seen a gain of 14.14% in its stock price over the last five trading days. benzinga.com reported 2024-07-31 that William Blair initiated coverage on Applied Therapeutics Inc. APLT, a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.
Is It Worth Investing in Applied Therapeutics Inc (NASDAQ: APLT) Right Now?
Company’s 36-month beta value is 2.03.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APLT is 85.82M, and currently, short sellers hold a 11.14% ratio of that floaft. The average trading volume of APLT on August 29, 2024 was 1.21M shares.
APLT’s Market Performance
APLT’s stock has seen a 14.14% increase for the week, with a 7.61% rise in the past month and a 45.27% gain in the past quarter. The volatility ratio for the week is 7.12%, and the volatility levels for the past 30 days are at 9.93% for Applied Therapeutics Inc The simple moving average for the past 20 days is 6.62% for APLT’s stock, with a 43.43% simple moving average for the past 200 days.
Analysts’ Opinion of APLT
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see APLT reach a price target of $12. The rating they have provided for APLT stocks is “Outperform” according to the report published on March 26th, 2024.
Leerink Partners gave a rating of “Outperform” to APLT, setting the target price at $12 in the report published on February 22nd of the current year.
APLT Trading at 18.46% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.93% of loss for the given period.
Volatility was left at 9.93%, however, over the last 30 days, the volatility rate increased by 7.12%, as shares surge +12.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.56% upper at present.
During the last 5 trading sessions, APLT rose by +13.75%, which changed the moving average for the period of 200-days by +213.79% in comparison to the 20-day moving average, which settled at $6.03. In addition, Applied Therapeutics Inc saw 90.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Funtleyder Leslie D., who sale 13,530 shares at the price of $5.83 back on Aug 22 ’24. After this action, Funtleyder Leslie D. now owns 277,911 shares of Applied Therapeutics Inc, valued at $78,880 using the latest closing price.
Perfetti Riccardo, the Chief Medical Officer of Applied Therapeutics Inc, sale 22,681 shares at $5.83 during a trade that took place back on Aug 22 ’24, which means that Perfetti Riccardo is holding 986,853 shares at $132,230 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- 234.34 for the present operating margin
- 3.12 for the gross margin
The net margin for Applied Therapeutics Inc stands at 483.75. The total capital return value is set at -1.08. Equity return is now at value -682.16, with -189.48 for asset returns.
Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -340.64. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -108.23.
Currently, EBITDA for the company is -64.18 million with net debt to EBITDA at 2.0. When we switch over and look at the enterprise to sales, we see a ratio of -1827.14. The receivables turnover for the company is -1.27for trailing twelve months and the total asset turnover is -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.30.
Conclusion
In a nutshell, Applied Therapeutics Inc (APLT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
